Advancements in CAR T-cell Therapies for NHL: Targeting CD5 and CD7 Antigens

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC, Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, Barbara Savoldo, MD, PhD, UNC School of Medicine, Chapel Hill, NC, and Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, discuss the latest updates in T-cell therapies for the treatment of NHL, commenting on real-world data on CD19-directed CAR-Ts, and exploring the potential of other T-cell therapies including CD30, CD20, and CD5-directed CAR-Ts in T-cell lymphomas.

The post iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells appeared first on VJHemOnc.